Skip to main content
TipRanks
Go Ultimate75% OFF

Fortress Biotech (FBIO) Stock Statistics & Valuation Metrics

1,597 Followers

Total Valuation

Fortress Biotech has a market cap or net worth of $62.70M. The enterprise value is -$23.99M.

Market Cap
$62.70M
Enterprise Value
-$23.99M

Share Statistics

Fortress Biotech has 33,350,994 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
33,350,994
Owned by Insiders
27.59%
Owned by Institutions
10.41%

Financial Efficiency

Fortress Biotech’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is -49.97%.

Return on Equity (ROE)
0.14
Return on Assets (ROA)
0.04
Return on Invested Capital (ROIC)
-49.97%
Return on Capital Employed (ROCE)
-0.52
Revenue Per Employee
811.05K
Profits Per Employee
87.37K
Employee Count
78
Asset Turnover
0.34
Inventory Turnover
2.17

Valuation Ratios

The current PE Ratio of Fortress Biotech is 0.65. Fortress Biotech’s PEG ratio is 0.00.

PE Ratio
0.65
PS Ratio
0.90
PB Ratio
0.40
Price to FCF
0.50
Price to Operating Cash Flow
0.50
PEG Ratio
0.00

Income Statement

In the last 12 months, Fortress Biotech had revenue of 63.26M and earned 6.82M in profits. Earnings per share was -0.07.

Revenue
63.26M
Gross Profit
42.34M
Operating Income
-70.22M
Pretax Income
-33.53M
Net Income
6.82M
EBITDA
-20.16M
Earnings Per Share (EPS)
-0.07

Cash Flow

In the last 12 months, operating cash flow was 125.83M and capital expenditures -86,000, giving a free cash flow of 125.75M billion.

Operating Cash Flow
125.83M
Free Cash Flow
125.75M
Free Cash Flow per Share
3.73

Dividends & Yields

Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
200.55%
Earnings Yield
157.81%

Stock Price Statistics

Beta
0.87
52-Week Price Change
-24.50%
50-Day Moving Average
2.14
200-Day Moving Average
2.71
Relative Strength Index (RSI)
42.47
Average Volume (3m)
286.61K

Important Dates

Fortress Biotech upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Apr 01, 2027
Ex-Dividend Date
―

Financial Position

Fortress Biotech as a current ratio of 2.49, with Debt / Equity ratio of 148.98%

Current Ratio
2.49
Quick Ratio
2.30
Debt to Market Cap
0.58
Net Debt to EBITDA
0.25
Interest Coverage Ratio
-8.06

Taxes

In the past 12 months, Fortress Biotech has paid -620.00K in taxes.

Income Tax
-620.00K
Effective Tax Rate
0.02

Enterprise Valuation

Fortress Biotech EV to EBITDA ratio is -0.35, with an EV/FCF ratio of -0.40.

EV to Sales
-0.72
EV to EBITDA
-0.35
EV to Free Cash Flow
-0.40
EV to Operating Cash Flow
-0.40

Balance Sheet

Fortress Biotech has $152.19M in cash and marketable securities with $38.95M in debt, giving a net cash position of $113.23M billion.

Cash & Marketable Securities
$152.19M
Total Debt
$38.95M
Net Cash
$113.23M
Net Cash Per Share
$3.40
Tangible Book Value Per Share
$4.52

Margins

Gross margin is 63.17%, with operating margin of -42.47%, and net profit margin of 143.05%.

Gross Margin
63.17%
Operating Margin
-42.47%
Pretax Margin
183.83%
Net Profit Margin
143.05%
EBITDA Margin
203.89%
EBIT Margin
196.76%

Analyst Forecast

The average price target for Fortress Biotech is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$5.00
Price Target Upside
165.96% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
12.34%
EPS Growth Forecast
―

Scores

Smart Score
6
AI Score
64